Takeda Pharmaceutica
4502
End-of-day quote Tokyo - 10/19
4641JPY
-1.34%
Income Statement Evolution
Annual Income Statement Data
Actuals in M JPY Estimates in M JPY
Fiscal Period March 20182019
Sales1 770 5311 765 055
EBITDA437 460413 059
Operating profit (EBIT)--
Pre-Tax Profit (EBT)217 205211 467
Net income186 886162 291
EPS ( JPY )239207
Dividend per Share ( JPY )180180
Yield3,47%3,88%
Announcement Date05/14/2018
06:00am
-
Finances - Leverage
Actuals in M JPY Estimates in M JPY
Fiscal Period March 20182019
Debt610 494679 746
Finance--
Operating income (EBITDA)437 460413 059
Leverage
(Debt/EBITDA)
1,40x1,65x
Capital Expenditure67 00588 151
Book Value Per Share (BVPS)2 557  JPY2 582  JPY
Cash Flow per Share490  JPY427  JPY
Announcement Date05/14/2018
06:00am
-
Balance Sheet Analysis
Financial Ratios
Size 2019e 2020e
Capitalization 3 688 199 M JPY -
Entreprise Value (EV) 4 367 946 M JPY 4 228 968 M JPY
Valuation 2019e 2020e
P/E ratio (Price / EPS) 22,4x 18,4x
Capitalization / Revenue 2,09x 2,03x
EV / Revenue 2,47x 2,33x
EV / EBITDA 10,6x 9,20x
Yield (DPS / Price) 3,88% 3,88%
Price to book (Price / BVPS) 1,80x 1,74x
Profitability 2019e 2020e
Operating Margin (EBIT / Sales) - -
operating Leverage (Delta EBIT / Delta Sales) - -
Net Margin (Net Profit / Revenue) 9,19% 12,0%
ROA (Net Profit / Asset) 4,77% 5,50%
ROE (Net Profit / Equities) 7,27% 9,62%
Rate of Dividend 86,8% 71,5%
Balance Sheet Analysis 2019e 2020e
CAPEX / CA   4,99% 4,36%
Cash Flow / Sales 19,0% 22,3%
Capital Intensity (Assets / Sales) 1,93x 2,18x
Financial Leverage (Net Debt / EBITDA) 1,65x 1,18x
Price Earning Ratio
BNA & Dividende